Business Context and Reporting Period
Company: PluriStem Therapeutics Inc.
Filing Type: Form 8-K (Current Report)
Date: November 10, 2016
Event: Entry into a Material Definitive Agreement regarding a private placement of securities.
Key Financial Metrics and Transaction Details
This filing reports a specific financing transaction rather than periodic financial performance metrics (revenue, profit, cash flow). The filing text does not provide current revenue, profit, or liquidity figures.
- Investment Amount: Approximately $30,000,000.
- Investor: Innovative Medical Management Co., Ltd. (China-based).
- Common Stock Issuance: Approximately 16,890,000 shares at $1.77 per share.
- Warrants Issued: Approximately 4,422,500 warrants with an exercise price of $2.50, exercisable for five years.
- Use of Proceeds: Support for late-stage clinical trials.
Material Changes and Agreements
The primary material change is the conversion of a previously announced term sheet into a binding agreement following approval by the investor's Board of Directors and shareholders.
- Definitive Agreements: Planned to be entered into no later than December 26, 2016.
- Financing Restriction: Until the earlier of December 26, 2016, or the execution of definitive agreements, the registrant cannot enter into equity financing at a price of $2.20 per share or less without prior written consent from Innovative Medical.
- Lock-up Period: Shares are subject to a 6-month lock-up agreement post-closing.
- Board Representation: Innovative Medical will receive one seat on the Board of Directors as long as it holds at least 12.5% of issued and outstanding stock.
- Additional Rights: Includes information, registration, preemptive rights, and negotiation rights regarding potential transactions in China.
Guidance, Risks, and Contingencies
Forward-Looking Statements: The filing contains forward-looking statements regarding the proposed private placement, terms, and use of proceeds. Management notes that while the Term Sheet is binding, definitive documentation may not be negotiated by the expected date, and the sale may not close if conditions are not met.
Regulatory Status: The securities have not been registered under the Securities Act of 1933. The registrant has agreed to file a registration statement for the resale of the shares and underlying warrants.
Risks: Actual results may differ materially from expectations due to uncertainties in negotiating definitive documentation and meeting closing conditions.
Investor Verification Checklist
- Verify the execution of definitive agreements by the December 26, 2016 deadline.
- Confirm the closing of the transaction and receipt of the $30,000,000 proceeds.
- Monitor the filing of the SEC registration statement for the resale of shares and warrants.
- Track the appointment of the new board member representing Innovative Medical.
- Review subsequent filings for updates on the progress of late-stage clinical trials funded by this investment.